Citius Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Pharmaceuticals, Inc. on October 26, 2016, covering events occurring on October 20, 2016. The filing discloses the entry into a material definitive agreement involving a new debt instrument.
Key Financial Metrics
The filing details a specific debt transaction rather than comprehensive financial performance metrics such as revenue, profit, or cash flow.
- New Debt Instrument: A second demand promissory note with a principal amount of $500,000.
- Interest Rate: Prime Rate (as published in the Wall Street Journal on the last day of the month) plus 1%.
- Maturity: The earlier of December 31, 2017, or upon demand by the Lender.
- Total Credit Facility: The Board authorized a revolving line of credit up to $2.5 million.
- Outstanding Balance: $1 million is currently outstanding (comprising the initial $500,000 note from September 7, 2016, and the new $500,000 note).
Material Changes
The primary material change is the increase in the company's short-term debt obligations. The company executed a new $500,000 note, bringing the total outstanding balance under the revolving credit facility to $1 million. The filing does not provide comparative financial data for prior periods regarding revenue or operating margins.
Management Commentary, Risks, and Related Parties
Related Party Transaction: The Lender is Leonard Mazur, who serves as the Company's Executive Chairman, Secretary, and a director. This constitutes a related-party transaction.
Terms: The notes function as a revolving loan, allowing the Company to repeatedly draw or repay funds up to the $2.5 million limit.
Risks: The debt is due on demand, creating potential liquidity pressure if the Lender calls the loan before the December 31, 2017 maturity date.
Key Facts for Investor Verification
- Verify the total outstanding debt of $1 million owed to Executive Chairman Leonard Mazur.
- Confirm the terms of the revolving credit facility, specifically the $2.5 million cap and the "Prime Rate + 1%" interest structure.
- Assess the Company's current liquidity position to determine its ability to repay the demand notes if called immediately.
- Review the full text of the Demand Promissory Note (Exhibit 10.1) for any covenants or default provisions not summarized in the 8-K.